NCT02476539View on ClinicalTrials.gov

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 14, 2015

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
HER2 Positive Breast Cancer
Interventions
DRUG

Hemay022

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Tianjin Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT02476539 - Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter